TP53 and myelodysplastic syndrome: Evidence also links CHIP to a higher risk of therapy-related myeloid neoplasms (MN), particularly following chemotherapy or radiation exposure, with tumor protein p53 (TP53) mutations playing a central role in predisposing to therapy-related leukemia and myelodysplastic syndromes (MDS).